Mark Worthington net worth and biography

Mark Worthington Biography and Net Worth

General Counsel of Athira Pharma

Mark joined LeonaBio as General Counsel in June 2021 after working with the company as outside corporate counsel for several years. He has advised private and public life sciences and other companies on a wide range of corporate governance, compliance and transactional matters, including public offerings, mergers and acquisitions, and joint ventures, and worked closely with executive management teams on strategic business and legal matters.

Prior to joining LeonaBio, Mark practiced corporate and securities law at Summit Law Group in Seattle, Washington, where he chaired the corporate/securities practice and served as the co-managing partner. He received his JD from University of California, Hastings College of the Law and BA from Stanford University.

What is Mark Worthington's net worth?: The estimated net worth of Mark Worthington is at least $107.78 thousand as of March 4th, 2026. Worthington owns 18,376 shares of Athira Pharma stock worth more than $107,775 as of September 23rd. This net worth estimate does not reflect any other investments that Worthington may own. Learn More about Mark Worthington's net worth.
How do I contact Mark Worthington?: The corporate mailing address for Worthington and other Athira Pharma executives is 18706 North Creek Parkway, Suite 104, Bothell, WA, 98011. Athira Pharma can also be reached via phone at 425-620-8501 and via email at [email protected]. Learn More on Mark Worthington's contact information.
Has Mark Worthington been buying or selling shares of Athira Pharma?: Mark Worthington has not been actively trading shares of Athira Pharma during the past quarter. Most recently, Mark Worthington sold 1,328 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $5.37, for a transaction totalling $7,131.36. Following the completion of the sale, the general counsel now directly owns 18,376 shares of the company's stock, valued at $98,679.12. Learn More on Mark Worthington's trading history.
Who are Athira Pharma's active insiders?: Athira Pharma's insider roster includes Mark Litton (CEO), and Mark Worthington (General Counsel). Learn More on Athira Pharma's active insiders.
Are insiders buying or selling shares of Athira Pharma?: In the last twelve months, insiders at the sold shares 8 times. They sold a total of 14,513 shares worth more than $86,093.34. The most recent insider tranaction occured on March, 4th when insider Martin Javier San sold 1,720 shares worth more than $9,236.40. Insiders at Athira Pharma own 25.7% of the company. Learn More about insider trades at Athira Pharma.
Information on this page was last updated on 3/4/2026.

Mark Worthington Insider Trading History at Athira Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2026	Sell	1,328	$5.37	$7,131.36	18,376
1/2/2026	Sell	876	$6.88	$6,026.88	13,978
7/1/2025	Sell	852	$2.90	$2,470.80	11,187
1/2/2025	Sell	851	$5.60	$4,765.60	8,373
1/5/2024	Sell	241	$29.10	$7,013.10	3,445
6/23/2022	Sell	261	$26.90	$7,020.90	1,909

Mark Worthington Buying and Selling Activity at Athira Pharma

Athira Pharma Company Overview

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Today's Range

Now: $5.90

$5.69

$6.35

50 Day Range

MA: $7.50

$6.05

$8.53

2 Week Range

Now: $5.90

$3.60

$14.21

Volume

20,175 shs

Average Volume

52,098 shs

Market Capitalization

$55.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.05